Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8543734 | 0.82 | HTR2A (0.46) | SLC6A3HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL11516181 | 0.81 | SLC6A2 (0.44) | SLC6A3HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL4001774 | 0.81 | MEN1 (0.52) | MAPTMEN1KMT2ALMNA | |
| SCHEMBL8485182 | 0.81 | DRD2 (0.41) | HTR2AHTR2CHTR2BGAAMEN1 | |
| Hydrochloric Acid SCHEMBL11553849 | 0.79 | MEN1 (0.50) | GAAMAPTMEN1KMT2ALMNA | |
| SCHEMBL11547755 | 0.79 | ALOX12 (0.43) | SLC6A3GAAMAPTMEN1KMT2A | |
| SCHEMBL8130957 | 0.77 | GID4 (0.53) | HTR2AHTR2CHTR2BGAAMEN1 | |
| SCHEMBL21856329 | 0.77 | HTR2C (0.48) | HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL30005837 | 0.76 | LMNA (0.67) | SLC6A3HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL880264 | 0.76 | LMNA (0.67) | SLC6A3HTR2AHTR2CHTR2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420015-A1 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2004-05-19 | — | — | EP | disclosed |
| EP-1097150-B1 | IMIDAZOLYL DERIVATIVES | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-24 | — | — | EP | disclosed |
| US-20040002531-A1 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTEFIQUES, S.A.S., A FRANCE CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-6509336-B1 | Prenyl transeferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2003-01-21 | — | — | US | disclosed |
| US-20030004342-A1 | Imidazolyl derivatives | BIOMEASURE, INC., A MASSACHUSETTS CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-6420555-B1 | IMIDAZOLE DERIVATIVES PRENYL TRANSFERASE INHIBITORS. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2002-07-16 | — | — | US | disclosed |
| EP-1097150-A1 | IMIDAZOLYL DERIVATIVES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2001-05-09 | — | — | EP | disclosed |
| EP-1094810-A1 | USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002558-A1 | USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-01-20 | — | — | WO | disclosed |
| WO-1999065898-A1 | IMIDAZOLYL DERIVATIVES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) | 1999-12-23 | — | — | WO | disclosed |
| US-4153789-A | HYPOGLYCEMIC AGENTS, ANTICOAGULANTS | DELMAR CHEMICALS LIMITED (CA) | 1979-05-08 | — | — | US | disclosed |
| US-4080330-A | HYPOGLYCEMIC AGENTS, ANTICOAGULANTS | DELMAR CHEMICALS LIMITED (CA) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004342-A1 | Imidazolyl derivatives | TPI1, BCHE, CYP51A1 | SLC6A3 1455/4885HTR2A 4446/4885HTR2C 3743/4885 |
| US-20040002531-A1 | Imidazolyl derivatives | TPI1, BCHE, CYP51A1 | SLC6A3 1455/4885HTR2A 4446/4885HTR2C 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.